SamRNA/mRNA-related Patent List
Key IP related to mRNA/saRNA/samRNA Medicines & Vaccines (up to 2022-12):
SamRNA.org
Patent Number Key Specification Priority/Status
US6197554B1 ** Full-length cDNA/mRNA generation (PCR-IVT) 1998-11 / EX
WO2000075356A1 Novel PCR-IVT for full-length mRNA amplification 1999-06 / NA
US09494212A1 Novel PCR-IVT for full-length mRNA amplification 2001-01 / EX
US09949305A1 2001-01 / EX
WO2002092774A2 Novel Replicase Cycling Reaction (RCR) 2001-05 / NA
US17489357A1 Improved Helicase-IVT for mRNA production 2021-06 / PD
US1764xxx6A1 Replicase Cycling Reaction (RCR) for samRNA amplification 2021-10 / PD
US1793xxx2A1 2021-10 / PD
US1847xxx3A1 Special designs of RdRP-binding sites (RdRP-BS) 2021-10 / PD
US1764xxx0A1 Use of samRNA for iPS cell generation 2021-10 / PD
US1815xxx1A1 Novel samRNA compositions (RdRP-BS-defined, non-replicon) 2021-10 / PD
** funded by USA NIH/NCI CA-85722.
ModernaTX
Patent Number Key Specification Priority/Status
US10064959B2 Synthetic mRNA with special modifications 2011-10 / ISU
WO2013151668 LNP-formulated mRNA with a 5’-UTR, coding region, 3’-UTR, 2013-03 / NA
US10577403B2 and ≥100-nucleotide poly(A) tail 2016-01 / ISU
US10703789B2 ** 2016-01 / ISU
US11246933B1 LNP composition designs for mRNA delivery 2021-04 / ISU
US11382979B2 2021-04 / ISU
US10702600B1 LNP-formulated mRNA vaccine against betaCoV 2015-10 / ISU
US10933127B2 2015-10 / ISU
WO2013151667 Translatable modified mRNA 2013-03 / NA
US10898574B2 Translatable modified mRNA 2012-04 / ISU
WO2014028429 RNA transcription methods (IVT) 2013-08 / NA
WO2014152027 RNA transcription methods (IVT) 2014-03 / NA
US14777190B2 RNA transcription methods (IVT) 2014-03 / PD
US16144282A1 2014-03 / PD
WO2015105926 Antibody-encoding mRNA 2015-08 / NA
US15106000A1 Antibody-encoding mRNA 2015-08 / PD
US20170002060 2015-08 / PD
US20190015501 mRNA vaccine designs 2018-09 / PD
** funded by USA NIH
Pfizer/BioNTech
Patent Number Key Specification Priority/Status
US07613066A1 Recombinant vaccine against coronaviral S protein 1990-11 / EX
US07698972A1 1990-11 / EX
US07882171A1 1990-11 / EX
EP0640096A1 Recombinant vaccine against coronaviral S protein 1993-05 / EX
WO2021213945A1 Container for coronavirus vaccine 2021-04 / NA
EP3901261A1 LNP-formulated mRNA encoding COVID S protein 2021-04 / PD
GlaxoSmithKline (GSK)
Patent Number Key Specification Priority/Status
EP2590670B1 Immunogen-encoding RNA 2010-07 / ISU
US11291635B2 Replicon (Alphavirus)-based self-replicating RNA (saRNA) 2011-07 / PD
WO2022137128A2 Replicon (Alphavirus)-based self-replicating RNA (saRNA) for 2020-12 / NA
US63129837A1 suppressing interferon response 2020-12 / EX
Novartis AG
Patent Number Key Specification Priority/Status
WO2006078294A2 Replicon (Alphavirus)-based self-replicating RNA (saRNA) 2004-05 / NA
US11291635B2 Replicon (Alphavirus)-based self-replicating RNA (saRNA) 2011-07 / PD
EP2451475A2 Self-replicating RNA (undefined saRNA, replicon?) 2009-07 / WD
WO2016066708A1 Antibody-encoding RNA (not saRNA/samRNA) 2014-10 / NA
EP3212224A1 Antibody-encoding RNA (not saRNA/samRNA) 2014-10 / ISU
EP3663315A1 2014-10 / ISU
US15520510A1 Antibody-encoding RNA (not saRNA/samRNA) 2014-10 / ISU
Arcturus Terapeutics, Inc.
Patent Number Key Specification Priority/Status
US11015204B2 Synthetic mRNA designs (not saRNA/samRNA) 2018-05 / ISU
US11407800B2 Translatable mRNA designs (not saRNA/samRNA) 2017-02 / ISU
WO2022056413A1 LNP-encapsulated large RNA (not saRNA/samRNA) 2020-09 / NA
Gritstone bio, Inc.
Patent Number Key Specification Priority/Status
EP3634449A4 Replicon (Alphavirus)-based samRNA vectors (saRNA) 2017-05 / PD
US11504421B2 Replicon (Alphavirus)-based samRNA vectors (saRNA) 2018-05 / ISU
US11510973B2 Alphavirus antigen vectors (saRNA) 2018-05 / ISU
Abnova
Patent Number Key Specification Priority/Status
US17836990A1 mRNA vaccine designs (not saRNA/samRNA) 2022-06 / PD
unpublished? Replicon (SARS-CoV-2)-based samRNA designs (saRNA) 2022-?? / PD
ISU = issued; PD = pending; EX = expired; WD = withdrawn; NA = not applicable.
